Compare GLSI & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLSI | SCM |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 267.2M |
| IPO Year | 2020 | 2012 |
| Metric | GLSI | SCM |
|---|---|---|
| Price | $21.90 | $8.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | $9.00 |
| AVG Volume (30 Days) | 130.9K | ★ 193.8K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $140.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.78 | $7.78 |
| 52 Week High | $34.10 | $15.39 |
| Indicator | GLSI | SCM |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 44.37 |
| Support Level | $21.16 | $7.78 |
| Resistance Level | $29.89 | $9.27 |
| Average True Range (ATR) | 2.17 | 0.30 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 61.02 | 45.56 |
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers.
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.